


IN THE CLAIMS:

Claims:

1. (original) A pharmaceutical composition in oral or systemic dosage form for administration to a mammalian patient comprising an effective amount of a compound to inhibit angiogenesis in said patient said compound having the structure:



wherein R^1 and R^2 are each independently selected from a C_1 to C_{20} saturated or unsaturated linear, cyclic or branch-chained substituted or unsubstituted hydrocarbon group, or a pharmaceutically acceptable salt thereof.

2. (amended) The composition according to claim 1, wherein R^1 and R^2 are each independently selected from a C_1 to C_{11} hydrocarbon group.

3. (amended) The composition according to claim 1 or 2, wherein R^1 or R^2 is an ester group.

4. (amended) The composition according to ~~any of claims 1-3~~ claim 1 wherein R^1 or R^2 contains an unsaturated group.

5. (amended) The composition according to ~~any of claims 1-4~~ claim 1 wherein R^1 or R^2 is a straight or branch-chained alkyl or alkenyl group, a cyclic alkyl group, an alkylphenyl group, alkenyl phenyl group, alkyl ester alkanoate or alkyl ester alkenoate group.

6. (amended) The composition according to ~~any of claims 1-5~~ claim 1 wherein R¹ and R² are each independently selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, 4-methylpentyl, 5-methylhexyl, cyclopentyl, cyclohexyl, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, 3-methylbutenyl, 5-methylhexenyl, benzyl, ethylbenzene, propylbenzene, ethyl propanoate and ethyl propenoate.

7. (amended) The composition according to ~~any of claims 1-6~~ claim 1 wherein R¹ is a methyl group.

8. (amended) A method of treating a tumor or cancer in a patient comprising administering to said patient an effective amount of the pharmaceutical composition according to ~~claim 1~~ any of claims 1-7 to said patient.

9-14. (cancelled)

15. (amended) ~~The method~~ A method of treating a tumor or cancer in a patient comprising administering to said patient an effective amount of the pharmaceutical composition according to ~~claim 8~~ any of claims 1-7 wherein said tumor is selected from the group consisting of neurofibromatosis, tuberous sclerosis, hemangiomas and lymphangiogenesis and said cancer is selected from the group consisting of cervical, anal and oral cancers, eye or ocular cancer, stomach, colon, bladder, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, renal, brain/cns, head and neck, throat, skin melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms Tumor, neuroblastoma, mouth/pharynx, esophageal, larynx, kidney and lymphoma.

16-21. (cancelled)

22. (original) A method of treating an angiogenic disorder in a patient comprising administering to said patient an effective amount of a pharmaceutical composition according to claim 1 to said patient.

23. (original) A method of treating an angiogenic disorder in a patient comprising administering to said patient an effective amount of a pharmaceutical composition according to claim 2 to said patient.

24-28. (cancelled)

29. (amended) ~~The~~ A method of treating an angiogenic disorder in a patient comprising administering to said patient an effective amount of a pharmaceutical composition according to claim ~~22~~ 1 or 2 wherein said angiogenic disorder is selected from the group consisting of psoriasis, venous ulcers, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, Sturge-Weber syndrome, neurofibromatosis, tuberous sclerosis, chronic inflammatory disease and arthritis.

30-37. (cancelled)